Senseonics (NYSE:SENS) said yesterday that is presenting long-term safety data on its Eversense CGM from a European post-market clinical follow up registry later this week, touting that results showed the device as having a strong safety profile.
The presentation is slated to take place this Saturday as part of the American Diabetes Association’s Scientific Sessions in San Francisco, the Germantown, Md.-based company said.
Read the whole story on our sister site, Drug Delivery Business News